Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL

Summary

The primary objectives are to evaluate the safety and tolerability of hLL1-DOX, and to determine the maximum tolerated dose (MTD) regimen (in terms of a dose and its associated dosing schedule). The secondary objectives are to obtain information on efficacy, pharmacodynamics, pharmacokinetics, and immunogenicity, and to determine the optimal dose for subsequent studies.

Timeline

Start

2012-08

Primary completion

2016-11

Completion

2017-10

Outcome

Outcome not reported

Stopped: “Study was terminated due to lack of efficacy, as a result, the stability program for the drug product was discontinued”

Drugs

Indications